Anika Therapeutics (AKP) AI Stock Analysis

Anika Therapeutics

(Frankfurt:AKP)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue and channel growthBroad-based revenue growth, including strong commercial and international performance, indicates improving demand across the portfolio rather than reliance on one isolated product. Sustained channel expansion can strengthen scale, support investment, and improve the company’s ability to compound sales over the next several quarters.

Negative Factors

Hyalofast FDA uncertaintyThe unresolved PMA review creates a structural commercialization risk for Hyalofast in the United States. Approval timing or an unfavorable outcome could delay market access, reduce expected portfolio contribution, and require the company to depend more heavily on existing products and international demand.

Anika Therapeutics (AKP) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 259.76M
Dividend Yield: ―
Average Volume (3M): 54
Price to Earnings (P/E): -72.0
Beta (1Y): 0.66
Revenue Growth: -9.02%
EPS Growth: 94.07%
Country: Germany
Employees: 235
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Anika Therapeutics Business Overview & Revenue Model

Company Description

Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain manag...

Anika Therapeutics Earnings Call Summary

Earnings Call Date:Jul 28, 2026(Q2-2026)|% Change Since:40.00%|Next Earnings Date:Nov 05, 2026

Earnings Call SentimentPositive

The call highlights clear commercial momentum (record international and commercial channel revenue), strong operational improvements (mid-60s gross margins, capacity expansions), and meaningful profitability gains (highest adjusted EBITDA since 2020) that supported upward guidance revisions. Key risks include FDA review uncertainty for Hyalofast, required CMC work for CINGAL, OEM revenue/order timing variability, modest U.S. pricing headwinds, and near-term cash conversion timing. Overall, positive execution and raised guidance outweigh the regulatory and timing headwinds.

Positive Updates

Total Revenue Growth

Q2 total revenue of $32.6M, up 16% year-over-year; year-to-date revenue up 14% to $62M.

Negative Updates

Regulatory Uncertainty for Hyalofast (U.S. PMA)

Hyalofast PMA under FDA review with a deficiency letter; co-primary endpoints are focal to the review and could impact approval timing; company removed the previously implied $3M of U.S. Hyalofast sales from 2027 guidance, increasing near-term uncertainty.

Company Guidance

Management raised full-year 2026 guidance: OEM channel revenue is now expected to grow 0%–5% (up from prior -5%–0%), commercial channel revenue 12%–18% (narrowed from 10%–20%), driving total company revenue to 5%–10% growth (up from 1%–9%); adjusted EBITDA margin guidance was raised to 13%–17% (from 5%–10%). They expect second-half profitability to be modestly lower than the first half due to OEM order timing, assume a relatively even Q3/Q4 split (implying strong year‑over‑year Q3 and moderate Q4), and will exclude unapproved products from future guidance (removing an implied $3M of U.S. Hyalofast sales), resulting in 2027 revenue guidance of 0%–5% growth. These updates follow strong first-half performance (YTD revenue +14% to $62.0M, Q2 revenue $32.6M +16% y/y), record international YTD revenue $23M (+17%), expanded gross margin to 65%, Q2 adjusted EBITDA of $7.1M (22% margin), $38.4M cash/no debt, and completion of a $15M share repurchase (shares ~13.3M).

Anika Therapeutics Risk Analysis

Anika Therapeutics disclosed 45 risk factors in its most recent earnings report. Anika Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Anika Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:AKP against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RCEL	54Neutral	$484.01M	-10.63	231.87%	―	1.00%	26.76%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
XTNT	45Neutral	$39.31M	-3.38	-23.45%	―	-14.27%	-132.84%
NSPR	43Neutral	$20.92M	-1.09	-79.21%	―	53.42%	22.08%

* Healthcare Sector Average

Performance Comparison

DE:AKP and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AKP	Anika Therapeutics, Inc.	18.20	9.85	117.96%
RCEL	Avita Medical Ltd	15.41	11.91	340.29%
NSPR	InspireMD Inc	0.54	-1.57	-74.45%
XTNT	Xtant Medical Holdings Inc	0.28	-0.52	-65.16%
MODD	Modular Medical Inc.	1.80	-13.00	-87.84%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Anika Therapeutics AI Stock Analysis